129 related articles for article (PubMed ID: 38582399)
21. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
22. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
23. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
24. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
[TBL] [Abstract][Full Text] [Related]
25. Amplicon-Based Targeted Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue.
Strengman E; Barendrecht-Smouter FAS; de Voijs C; de Vree P; Nijman IJ; de Leng WWJ
Methods Mol Biol; 2019; 1908():1-17. PubMed ID: 30649717
[TBL] [Abstract][Full Text] [Related]
26. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders.
Jajosky AN; Havens NP; Sadri N; Oduro KA; Moore EM; Beck RC; Meyerson HJ
Am J Clin Pathol; 2021 Aug; 156(3):433-444. PubMed ID: 33712839
[TBL] [Abstract][Full Text] [Related]
28. Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.
Garg S; Grenier S; Misyura M; Sukhai MA; Thomas M; Kamel-Reid S; Stockley T
J Mol Diagn; 2020 Apr; 22(4):467-475. PubMed ID: 32036084
[TBL] [Abstract][Full Text] [Related]
29. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
30. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
31. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
[TBL] [Abstract][Full Text] [Related]
32. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders.
Stewart JP; Gazdova J; Darzentas N; Wren D; Proszek P; Fazio G; Songia S; Alcoceba M; Sarasquete ME; Villarese P; van der Klift MY; Heezen KC; McCafferty N; Pal K; Catherwood M; Kim CS; Srivastava S; Kroeze LI; Hodges E; Stamatopoulos K; Klapper W; Genuardi E; Ferrero S; van den Brand M; Cazzaniga G; Davi F; Sutton LA; Garcia-Sanz R; Groenen PJTA; Macintyre EA; Brüggemann M; Pott C; Langerak AW; Gonzalez D;
Blood Adv; 2021 Aug; 5(16):3188-3198. PubMed ID: 34424321
[TBL] [Abstract][Full Text] [Related]
33. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.
Scheijen B; Meijers RWJ; Rijntjes J; van der Klift MY; Möbs M; Steinhilber J; Reigl T; van den Brand M; Kotrová M; Ritter JM; Catherwood MA; Stamatopoulos K; Brüggemann M; Davi F; Darzentas N; Pott C; Fend F; Hummel M; Langerak AW; Groenen PJTA;
Leukemia; 2019 Sep; 33(9):2227-2240. PubMed ID: 31197258
[TBL] [Abstract][Full Text] [Related]
36. Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
Gil JV; Such E; Sargas C; Simarro J; Miralles A; Pérez G; de Juan I; Palanca S; Avetisyan G; Santiago M; Fuentes C; Fernández JM; Vicente AI; Romero S; Llop M; Barragán E
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901871
[TBL] [Abstract][Full Text] [Related]
37. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.
Lin MT; Mosier SL; Thiess M; Beierl KF; Debeljak M; Tseng LH; Chen G; Yegnasubramanian S; Ho H; Cope L; Wheelan SJ; Gocke CD; Eshleman JR
Am J Clin Pathol; 2014 Jun; 141(6):856-66. PubMed ID: 24838331
[TBL] [Abstract][Full Text] [Related]
38. The role of molecular biology in the diagnosis of lymphoid neoplasms.
Pizzi M; Gazzola A; Mannu C; Pileri SA; Sabattini E; Pileri SA
Front Biosci (Landmark Ed); 2014 Jun; 19(7):1088-104. PubMed ID: 24896338
[TBL] [Abstract][Full Text] [Related]
39. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.
Kanagal-Shamanna R; Singh RR; Routbort MJ; Patel KP; Medeiros LJ; Luthra R
Expert Rev Mol Diagn; 2016; 16(4):461-72. PubMed ID: 26765348
[TBL] [Abstract][Full Text] [Related]
40. Targeted exome sequencing and chromosomal microarray for the molecular diagnosis of nevoid basal cell carcinoma syndrome.
Matsudate Y; Naruto T; Hayashi Y; Minami M; Tohyama M; Yokota K; Yamada D; Imoto I; Kubo Y
J Dermatol Sci; 2017 Jun; 86(3):206-211. PubMed ID: 28342698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
